Some studies suggest a need for cardiologists to rethink their approach to device implant. However, the TAVR UNLOAD study failed to demonstrate a statistically significant difference between device implant and medical management for patients with aortic stenosis and low left ventricular ejection fraction. Read More
The U.S. FDA’s approval of the Abbott Laboratories Triclip was predicated on a data set comprised of 350 patients, but an additional bolus of data seems to reinforce the rationale for the FDA approval, including improvements in quality of life. Read More
Shockwave Medical, a unit of New Brunswick, N.J.-based Johnson & Johnson Medtech, completed enrollment in the first prospective all-female study of percutaneous coronary intervention in complex disease. The real-world, all-comers trial will evaluate the benefits of coronary intravascular lithotripsy in female patients with calcified lesions. Read More
A major increase in the popularity of weight loss drugs, particularly GLP-1s, has created a rivalry with traditional device orientated approaches, but a new technology aims to navigate the space between them. Read More
Ngenebio Co. Ltd. launched a precision diagnostic panel called Oncoaccupanel RNA in South Korea Oct. 29 as a test to detect oncogenic fusion genes commonly found in solid tumors. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Cardiawave, Cardiosense, Cleerly, Egnite, Elixir, Medtronic, Mitrassist Lifesciences. Read More
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Brook Health, Cogstate, Dassault, Linus Health, Medidata, Medlumics, MGI Tech, Neuraxis, Oncodna, Philips, Qure.ai, Roche Diagnostics, Revvity, Sherlock Biosciences, Startup Creasphere, Themednet. Read More
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: GT Metabolic Solutions, Insulcloud, Qiagen, Syntheticmr. Read More
